Private Capital Advisors Inc. Takes $323,000 Position in Regeneron Pharmaceuticals, Inc. $REGN

Private Capital Advisors Inc. purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 616 shares of the biopharmaceutical company's stock, valued at approximately $323,000.

Other large investors have also modified their holdings of the company. Creative Financial Designs Inc. ADV increased its position in shares of Regeneron Pharmaceuticals by 9.5% in the first quarter. Creative Financial Designs Inc. ADV now owns 220 shares of the biopharmaceutical company's stock worth $139,000 after acquiring an additional 19 shares in the last quarter. Private Trust Co. NA grew its holdings in Regeneron Pharmaceuticals by 13.1% during the 1st quarter. Private Trust Co. NA now owns 164 shares of the biopharmaceutical company's stock valued at $104,000 after purchasing an additional 19 shares in the last quarter. Proficio Capital Partners LLC grew its holdings in Regeneron Pharmaceuticals by 6.2% during the 1st quarter. Proficio Capital Partners LLC now owns 327 shares of the biopharmaceutical company's stock valued at $207,000 after purchasing an additional 19 shares in the last quarter. Cove Private Wealth LLC grew its holdings in Regeneron Pharmaceuticals by 4.5% during the 1st quarter. Cove Private Wealth LLC now owns 460 shares of the biopharmaceutical company's stock valued at $292,000 after purchasing an additional 20 shares in the last quarter. Finally, Marino Stram & Associates LLC grew its holdings in Regeneron Pharmaceuticals by 5.3% during the 2nd quarter. Marino Stram & Associates LLC now owns 396 shares of the biopharmaceutical company's stock valued at $208,000 after purchasing an additional 20 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Citigroup raised their price target on shares of Regeneron Pharmaceuticals from $650.00 to $660.00 and gave the company a "buy" rating in a report on Monday, October 13th. BMO Capital Markets raised their price target on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an "outperform" rating in a report on Monday, August 4th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $850.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, October 14th. Weiss Ratings reissued a "hold (c-)" rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 8th. Finally, Rothschild & Co Redburn assumed coverage on shares of Regeneron Pharmaceuticals in a report on Thursday, August 14th. They set a "buy" rating and a $890.00 price objective for the company. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $817.88.

Regeneron Pharmaceuticals Trading Up 0.4%

Regeneron Pharmaceuticals stock opened at $579.34 on Wednesday. The firm's 50-day moving average is $575.71 and its 200-day moving average is $562.26. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $972.74. The company has a market cap of $61.40 billion, a P/E ratio of 14.60, a PEG ratio of 1.80 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company had revenue of $3.68 billion for the quarter, compared to the consensus estimate of $3.30 billion. During the same period last year, the firm posted $11.56 EPS. The company's revenue for the quarter was up 3.6% on a year-over-year basis. On average, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were given a $0.88 dividend. The ex-dividend date was Monday, August 18th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.